

Director of the United States Patent and Trademark Office



US011058718B2

(12) **United States Patent**
Kubota et al.

(10) **Patent No.: US 11,058,718 B2**
(45) **Date of Patent: Jul. 13, 2021**

(54) **METHOD FOR TREATING
NON-ALCOHOLIC STEATOHEPATITIS
(NASH) WITH THE COMBINATION OF
POLAPREZINC AND SODIUM SELENITE**

(71) Applicant: **Medico Consl Co., Ltd.**, Osaka (JP)

(72) Inventors: **Satoru Kubota**, Osaka (JP); **Toru Kono**, Hokkaido (JP)

(73) Assignee: **MEDICO CONSL CO., LTD.**, Suita (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/892,728**

(22) Filed: **Jun. 4, 2020**

(65) **Prior Publication Data**

US 2020/0405754 A1 Dec. 31, 2020

Related U.S. Application Data

(63) Continuation-in-part of application No. 16/473,888, filed on Jun. 26, 2019, now abandoned.

(51) **Int. Cl.**
A61K 33/30 (2006.01)
A61P 1/16 (2006.01)
A61K 33/04 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 33/30** (2013.01); **A61K 33/04** (2013.01); **A61P 1/16** (2018.01)

(58) **Field of Classification Search**
USPC 514/494
See application file for complete search history.

(56) **References Cited**

PUBLICATIONS

Sugino (Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis, *Journal of Gastroenterology and Hepatology* 23, 2008, pp. 1909-1916).*

Ming Ding (Selenium Supplementation Decreases Hepatic Fibrosis in Mice After Chronic Carbon Tetrachloride Administration, *Biol Trace Elem Res*, 2010, 133(1), pp. 83-97).*

Japanese Notification of Reasons for Refusal mailed by Japanese Patent Office dated Jan. 27, 2020 in corresponding Japanese patent application No. 2019-516717.

Li, Tan et al., Vitamin E and Se interfere in cytochrome P4501A1 and lipid peroxidation in nonalcoholic fatty liver, *World Chinese Journal of Digestology*, Oct. 8, 2007, vol. 15, No. 28, ISSN:1009-3079, p. 2977-2982.

Japanese Decision of Refusal mailed by Japanese Patent Office dated Apr. 13, 2020 in corresponding Japanese patent application No. 2019-516717.

Chinese Notification of Reasons for Refusal mailed by Chinese Patent Office dated Nov. 11, 2020 in corresponding Chinese patent application No. 201780069336.5.

Haruko Sugino et al., Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis, *Journal of Gastroenterology and Hepatology*, vol. 23, p. 1909-1915.

Ma Na, Sodium selenite improves nonalcoholic fatty liver disease by reversing abnormal thyroid hormone transformation, Chinese excellent masters thesis collection (medical health science technology) issue02, p. 38.

Ashwani K. Signal et al., Antioxidants as therapeutic agents for liver disease, *Liver International*. 1432-1448.

* cited by examiner

Primary Examiner — Kathrien A Cruz

(74) *Attorney, Agent, or Firm* — IP Business Solutions, LLC

(57) **ABSTRACT**

Provided is a method for treating non-alcoholic steatohepatitis (NASH), the method includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition and the pharmaceutical composition contains polaprezinc as zinc preparation and sodium selenite as selenium preparation.

1 Claim, 11 Drawing Sheets
(3 of 11 Drawing Sheet(s) Filed in Color)